108 results about "Nf kappab" patented technology

Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain NF-kappaB inhibitors, particularly certain dialkyl fumarates, are disclosed. Dimethyl fumarate is a particularly preferred dialkyl fumarate. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the dialkyl fumarate with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-dialkyl fumarate blends are disclosed. Additionally, medical devices having a coating comprising at least one dialkyl fumarate in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.

The invention provides methods for the inhibition of inflammation by providing, to a cell, in need thereof, monoterpene compositions that inhibit NF-κB. These compositions may also contain a carrier moiety that renders the monoterpene composition membrane permeable. The carrier may include triterpenoid moieties, sugars, lipids, or even additional monoterpenoid moieties. The composition can also contain additional chemical functionalities. Methods for using these compounds to prevent and treat a wide range of inflammatory conditions, especially, premalignant inflammatory conditions are described.

The invention relates to the field of human or veterinary medicine and to the treatment of subjects (be it man or animal) that suffer from iatrogenic disease, i.e., experience problems or complications resulting from a medical treatment. Provided is a method for modulating an iatrogenic event in a subject, the method comprising: providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, provided is the use of an NF-kappaB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of an additional pro-inflammatory cytokine response occurring after an iatrogenic event in a subject.

The present invention relates to compounds of the Formula (I), wherein X₁ and X₂ independently represent O, NH or S; R₁ and R₂ are independently selected from the group consisting of a C1-C30 hydrocarbyl group, an amino acid bonded via an amide bond or a peptide bonded via an amide bond each having up to 200 amino acids, the conjugated residue X₁ or X₂ in this case being NH, and hydrogen, both radicals R₁ and R₂ preferably not being H; and R₃ is a residue selected from group consisting of —S—R₆, wherein R₆ is a C1-C30 hydrocarbyl group, at least one of R₁ and R₂ not being H when X₁ and X₂ are oxygen, —S—CH₂—CH(NH₂)(COOH) (cysteine-S-yl), a homologue or derivative (e.g. N-acetyl cysteine-S-yl) thereof, a peptide having up to 200 amino acids which contains at least one amino acid radical with a thiol group, preferably a cysteine radical, and is bonded via the thio sulfur, preferably via the cysteine sulfur (peptide-S-yl), coenzyme A which is bonded via a thiol group or fragments thereof, acyl carrier protein bonded via a thiol group, and dihydrolipoic acid bonded via a thiol group; and pharmaceutically acceptable salts thereof. The present invention also relates to the use of these compounds for preparing a drug, drugs containing the same and their use for the therapy of diseases such as autoimmune disease, NF-kappaB mediated diseases, psoriasis, psoriatic arthritis, neurodermitis, enteris regionalis Crohn, cardiac insufficiency, chronic obstructive pulmonary diseases and asthma and in transplantation medicine.

Salicylamide derivatives represented by formulae (1a) and (1b); intermediates in the production thereof; a process for producing the same; and drugs containing the same as the active ingredient. The salicylamide derivatives represented by formulae (1a) and (1b) are useful as anti-inflammatory agents and immunosuppressive agents which exert an effect of inhibiting the activation of NF-kappaB with little side effects.

A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I)

its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR¹R² or CH²NR¹R² and where at least two of X₁-X₄ and/or X₅-X₈ is N or NR¹⁸, and R, R^a, R^b, R^c, R^d, R¹, R² and R¹⁸ are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-κB, and methods for treating diseases in which activation of NF-κB is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-κB activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.

The invention discloses a kind of human gene CTRP4 and its coding CTRP4 protein. The invention also relates to the application of an antagonist of the gene and protein in the preparation of NF-kappaB and/or IL6-STAT3 pathway activity inhibiting drug, and relates to the application of an agonist of the gene and the protein in the preparation of hematopoiesis promoting drug and GP130 molecule up-regulating drug.

A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc.), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-kappaB as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants.

A brain-protective agent containing an NF-kappaB decoy. In brain diseases, the brain can be particularly effectively protected against brain disorders (for example, cerebral vasospasm following a subrachnoidal hemorrhage and apoptosis of the nerve cells following a cerebrovasucular accident or serious head injury) caused by the undesired activation of cytokines or cell adhesion factors which are regulated by NF-kappaB by administering the brain-protective agent containing an NF-kappaB decoy, i.e., a compound antadonistic specifically to a nucleic acid to which NF-kappaB binds.

The invention discloses preparation and immune-enhancement use of lucid ganoderma liquid fermentation extracellular active polysaccharides. Lucid ganoderma strains are transferred into a flat PDA medium, then is inoculated to a liquid medium with inoculums size of 10%, and is correspondingly inoculated to a liquid medium with glucose, galactose, mannose, fructose and the like as carbon sources andyeast powder or yeast extracts as nitrogen sources for culturing, ethyl alcohol is added to make the final concentration is 20%-30%, collecting and precipitating are conducted, and drying is conducted after washing by 20%-30% of the ethyl alcohol for 2-3 times, the level of fetal alkaline phosphatase (SEAP) is determined by a QUANTI-Blue method, and the activity of NF-kappaB is activated by an evaluation sample through a Dectin-1 pathway. The results show that the lucid ganoderma fermentation extracellular polysaccharides obtained by the method all have the activity of activating NF-kappaB, and the obtainedpolysaccharides have very good immune activity.

A pharmaceutical composition for treating and preventing diseases, disorders and/or conditions of airway inflammation, airway stenosis or nasal cavity inflammation caused by the expression of a gene regulated by NF-kappaB which contains an NF-kappaB decoy and a pharmaceutically acceptable carrier. The above diseases may be asthma, COPD or rhinitis. Moreover, the above diseases may be diseases caused by an eosinophil abnormality (for example, asthma, rhinitis and COPD). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome and so on.